CoChat

Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders

Glue, Paul, Medlicott, Natalie J, Harland, Sarah, Neehoff, Shona, Anderson-Fahey, Bridie, Le Nedelec, Martin, Gray, Andrew, McNaughton, Neil · 2017 · Journal of Psychopharmacology

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities in brain network activity in depression and anxiety disorders, we hypothesized that ketamine might also be active in other refractory anxiety disorders. We evaluated the efficacy and safety of ketamine in 12 patients with refractory generalized anxiety disorder and/or social anxiety disorder who were not currently depressed, using an ascending single dose study design (0.25, 0.5, 1 mg/kg administered subcutaneously) at weekly intervals. Within 1 h of dosing, patients reported reduced anxiety, which persisted for up to seven days. A dose-response profile was noted for anxiolytic effects, dissociative side effects, and changes in blood pressure and heart rate, with minor changes at 0.25 mg/kg, and progressively greater and more durable changes at the higher doses. Ten of 12 patients were treatment responders at 0.5–1 mg/kg. Ketamine was safe and well tolerated in this population. Ketamine may be a potential therapeutic alternative for patients with refractory generalized anxiety disorder/social anxiety disorder. Along with its demonstrated effectiveness in patients with treatment-resistant depression, obsessive compulsive disorder and post-traumatic stress disorder, these data raise the intriguing possibility that ketamine may have broad efficacy in disorders characterized by negative emotional states, and that these disorders may share a common precipitating neurobiology.

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881117705089

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

See all 144

Metadata

Authors
Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N.
Affiliations
  • University of Otago (NZ)
  • Department of Psychological Medicine, University of Otago, Dunedin, New Zealand
Corresponding author
Glue, Paul
Venue
Journal of Psychopharmacology
Published
2017-04-26
Volume
31
Issue
10
Pages
1302-1305
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2608289281
Cited by
144
References
19
Citations by year
2026: 8 · 2025: 16 · 2024: 36 · 2023: 11 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 10 · 2018: 10 · 2017: 8
FWCI
8.02
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
ketamine, generalized anxiety disorder, social anxiety disorder, NMDA receptor antagonists, dose-response relationship, anxiolytic effects, blood pressure and heart rate changes, rapid-acting antidepressants, safety and tolerability
MeSH terms
Adult, Antidepressive Agents, Anxiety, Anxiety Disorders, Depression, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Ketamine, Male, Middle Aged, Obsessive-Compulsive Disorder, Stress Disorders, Post-Traumatic, Anti-Anxiety Agents, Receptors, N-Methyl-D-Aspartate, Young Adult, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. https://app.cochat.ai/papers/10.1177/0269881117705089
The paper
Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017). Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117705089

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.